Skip Navigation LinksHome > September/October 2013 - Volume 37 - Issue 5 > Gadofosveset-Enhanced Magnetic Resonance Angiography of the...
Journal of Computer Assisted Tomography:
doi: 10.1097/RCT.0b013e318299dde9
Thoracic and Cardiovascular Imaging

Gadofosveset-Enhanced Magnetic Resonance Angiography of the Thoracic Vasculature in the Equilibrium Phase: Feasibility and Impact of Dose

Kim, Charles Y. MD*; Heye, Tobias MD; Bashir, Mustafa R. MD*; Gebhard, Thomas A. MD*; Merkle, Elmar M MD

Collapse Box

Abstract

Objective

The objectives of this study were to evaluate the feasibility of gadofosveset-enhanced magnetic resonance angiography (MRA) of the thoracic vasculature in the equilibrium phase and to determine the impact of gadofosveset dose on imaging quality.

Methods

Thirty healthy volunteers were randomized to receive a dose of 0.03, 0.02, or 0.01 mmol/kg of gadofosveset for MRA at 3 T in the equilibrium phase. Two radiologists assessed the central veins, the pulmonary arteries, and the thoracic aorta. Quantitative assessments were also performed.

Results

At 0.03 and 0.02 mmol/kg, all vessel segments were rated as adequate. At a dose of 0.01 mmol/kg, less than 10% of vascular segments were collectively rated as inadequate. The signal-to-noise ratio and contrast-to-noise ratio were significantly lower in all segments at 0.01 mmol/kg compared with higher doses.

Conclusions

Gadofosveset-enhanced MRA of the thoracic vessels in the equilibrium phase in healthy volunteers resulted in adequate vessel visualization, even when dose reduction was performed.

This trial was registered with clinicaltrials.gov, identifier NCT01431300.

Copyright © 2013 by Lippincott Williams & Wilkins

  

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.